OSTX

Os Therapies Inc. (OSTX) | Rumor.io

Os Therapies

OSTX

Attention (50-day avg)0.08%

Attention rank (50-day avg)#133

Bullish sentiment (50-day avg)90%

Price to earnings ratio-1.68

Net assets77.2M

Expense ratio0%

Social

What share of all ETF conversation is about OSTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.1% +0.07	0.06% -0.1	0.12% +0.1	0.01% +0

Sep 23

OS Therapies Incorporated's ($OSTX) numbers are strong, and the company should be up despite the biotech sector's decline.
The $1.65 level provides a safe place to add to positions, with strong support from investors.
Recent good news has not been reflected in the stock price, with many sellers despite the fundamentals remaining unchanged.

Generated by AI

Sentiment

Of the messages about OSTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	90.91% -9.09	89.23% +1.99	89.95% -4.62	91.13% +3.39
Bearish	9.09% new	10.77% -1.99	10.05% +4.62	8.88% -3.39

Bullish· Sep 17

The project Orbis announcement represents a strategic regulatory shift in the most positive way, enabling a Type A global review for regulatory approval, which is the fastest way to gain approval.
$OSTX has the potential to jump to $7 and beyond due to its current undervalued price, making it a good investment opportunity.
The company's path forward is becoming increasingly clear, with the number of potential partners set to increase significantly, and FDA/EMA/UK approval expected to be a major catalyst for the stock.

Bearish· Jun 2

The 2.5-year overall survival rate for OST-HER2 is 75%, but this may not be sustained in the long term, with some analysts expecting a decline to 50-60% at the 3-year mark.
The company's funding situation is precarious, with some investors warning of dilution and the potential for the company to dump shares onto investors.
The recent announcement of a 75% 2.5-year overall survival rate for OST-HER2 may be a "sell the news" opportunity, with some investors expecting a sharp decline in the stock price.

Generated by AI

Topics

Of the messages about OSTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	100%	99.73%	99.51%
Macro	0%	0%	0.27%	0.49%

Sep 21

The FDA has accepted OS Therapies' OST-HER2 project under Project Orbis, a program for expedited review of cancer therapies.
The company has completed a Type C Statistical Methods Meeting with the FDA, which resulted in alignment on an amended Phase 3 study design, and is awaiting decisions on RMAT, Rolling Review, and CNPV.
The use of OSTX historical data in the Type C meeting was not validated by the FDA, which may affect the company's Q4 timelines, with some investors interpreting the outcome as neutral or slightly disappointing.

Generated by AI

Community

Of the messages about OSTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	98.75%	74.59%	64.03%	66.56%
Newcomers	1.25%	25.41%	35.97%	33.44%

Regulars· Sep 17

The FDA has aligned with the UK and European regulators on the proposed design for OS Therapies' Phase 3 trial, overcoming a key hurdle for the trial's initiation in the UK and beyond.
The UK's MHRA has invited OS Therapies into Project Orbis, a program designed to coordinate the review of promising oncology treatments, potentially leading to a Type A global framework review and concurrent approval decision across participating agencies.
OS Therapies is positioning for a Type A global framework review, which could lead to a concurrent approval decision across all participating global agencies, and the company's Priority Review Voucher eligibility under RPDD if the OST-HER2 BLA is approved.

Newcomers· Sep 17

The FDA has aligned with the MHRA and EMA on the adaptive Phase 3 design for OS Therapies' OST-HER2 trial, with the trial expected to begin in Q4 2026.
OS Therapies has accepted Project Orbis' invitation from the MHRA, which could provide additional regulatory clarity and support for the company's metastatic osteosarcoma program.
The Phase 3 trial's design and the company's regulatory progress may not be fully priced into the stock yet, with some analysts expecting further updates and confirmations before a full re-rating of the company's valuation.

Generated by AI

News

Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON)

Detailed price information for Concentra Group Holdings Parent Inc (CON-N) from The Globe and Mail including charting and trades.

21d agoThe Globe and Mail

OS Therapies Announces Convertible Note Financing and Warrants

Tipranks Press Release.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about OSTX also mention

#	Name	Attention
1	Rein Therapeutics Inc.RNTX	0%0
2	PolyPid Ltd.PYPD	0%new
3	Unicycive Therapeutics Inc.UNCY	0%new
4	Candel Therapeutics, Inc.CADL	0.02%+0.01
5	Cingulate Inc.CING	0%new
6	Aligos Therapeutics, Inc.ALGS	0%new
7	Ainos, Inc.AIMD	0%+0
8	CleanCore Solutions Inc. Class B Common StockZONE	0%+0
9	Veea Inc.VEEA	0%0
10	DataMeds AI Inc.MEDS	0%-0.02

Os Therapies Inc.

Healthcare
Biotechnology

Os Therapies Inc. is a biotechnology company focused on the development and commercialization of innovative cancer treatments. Their primary function is to research and produce therapies aimed at improving the prognosis and quality of life for cancer patients. The company is particularly engaged in the immunotherapy sector, conducting trials and developing products that help harness the body’s immune system to fight cancer. Os Therapies Inc. plays a significant role in the biotechnology and pharmaceutical industries by striving to bring transformative solutions to oncological challenges. As part of the broader healthcare sector, their work contributes to advancements in personalized medicine and addresses pressing needs in cancer treatment methodologies. Through its cutting-edge research and dedicated approach, Os Therapies Inc. seeks to make impactful contributions to both patients' lives and the scientific community's understanding of cancer treatment.

Location

United States

Social

What share of all ETF conversation is about OSTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.1% +0.07	0.06% -0.1	0.12% +0.1	0.01% +0

Sep 23

OS Therapies Incorporated's ($OSTX) numbers are strong, and the company should be up despite the biotech sector's decline.
The $1.65 level provides a safe place to add to positions, with strong support from investors.
Recent good news has not been reflected in the stock price, with many sellers despite the fundamentals remaining unchanged.

Generated by AI

Sentiment

Of the messages about OSTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	90.91% -9.09	89.23% +1.99	89.95% -4.62	91.13% +3.39
Bearish	9.09% new	10.77% -1.99	10.05% +4.62	8.88% -3.39

Bullish· Sep 17

The project Orbis announcement represents a strategic regulatory shift in the most positive way, enabling a Type A global review for regulatory approval, which is the fastest way to gain approval.
$OSTX has the potential to jump to $7 and beyond due to its current undervalued price, making it a good investment opportunity.
The company's path forward is becoming increasingly clear, with the number of potential partners set to increase significantly, and FDA/EMA/UK approval expected to be a major catalyst for the stock.

Bearish· Jun 2

The 2.5-year overall survival rate for OST-HER2 is 75%, but this may not be sustained in the long term, with some analysts expecting a decline to 50-60% at the 3-year mark.
The company's funding situation is precarious, with some investors warning of dilution and the potential for the company to dump shares onto investors.
The recent announcement of a 75% 2.5-year overall survival rate for OST-HER2 may be a "sell the news" opportunity, with some investors expecting a sharp decline in the stock price.

Generated by AI

Topics

Of the messages about OSTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	100%	99.73%	99.51%
Macro	0%	0%	0.27%	0.49%

Sep 21

The FDA has accepted OS Therapies' OST-HER2 project under Project Orbis, a program for expedited review of cancer therapies.
The company has completed a Type C Statistical Methods Meeting with the FDA, which resulted in alignment on an amended Phase 3 study design, and is awaiting decisions on RMAT, Rolling Review, and CNPV.
The use of OSTX historical data in the Type C meeting was not validated by the FDA, which may affect the company's Q4 timelines, with some investors interpreting the outcome as neutral or slightly disappointing.

Generated by AI

Community

Of the messages about OSTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	98.75%	74.59%	64.03%	66.56%
Newcomers	1.25%	25.41%	35.97%	33.44%

Regulars· Sep 17

The FDA has aligned with the UK and European regulators on the proposed design for OS Therapies' Phase 3 trial, overcoming a key hurdle for the trial's initiation in the UK and beyond.
The UK's MHRA has invited OS Therapies into Project Orbis, a program designed to coordinate the review of promising oncology treatments, potentially leading to a Type A global framework review and concurrent approval decision across participating agencies.
OS Therapies is positioning for a Type A global framework review, which could lead to a concurrent approval decision across all participating global agencies, and the company's Priority Review Voucher eligibility under RPDD if the OST-HER2 BLA is approved.

Newcomers· Sep 17

The FDA has aligned with the MHRA and EMA on the adaptive Phase 3 design for OS Therapies' OST-HER2 trial, with the trial expected to begin in Q4 2026.
OS Therapies has accepted Project Orbis' invitation from the MHRA, which could provide additional regulatory clarity and support for the company's metastatic osteosarcoma program.
The Phase 3 trial's design and the company's regulatory progress may not be fully priced into the stock yet, with some analysts expecting further updates and confirmations before a full re-rating of the company's valuation.

Generated by AI

Os Therapies

Social

Sep 23

Bullish· Sep 17

Bearish· Jun 2

Sep 21

Regulars· Sep 17

Newcomers· Sep 17

Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON)

OS Therapies Announces Convertible Note Financing and Warrants

Also Discussed

Os Therapies Inc.

Company Information

Location

Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON)

OS Therapies Announces Convertible Note Financing and Warrants

Also Discussed

Social

Sep 23

Bullish· Sep 17

Bearish· Jun 2

Sep 21

Regulars· Sep 17

Newcomers· Sep 17